Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists

Background: Despite successes in the development of innovative anticancer therapies, the fiscal and capacity restraints of the Canadian public healthcare system result in challenges with drug access. A meaningful proportion of systemic therapies ultimately do not receive public funding despite supporting clinical evidence. In this study, we assessed Canadian medical oncologists’ current attitudes toward discussing publicly unfunded cancer treatments with patients and predictors of different practices. Methods: A web-based survey consisting of multiple choice and case-based scenarios was distributed to medical oncologists identified through the Royal College of Physicians and Surgeons of Canada directory. Results: A total of 116 responses were received. Almost all respondents reported discussing publicly unfunded treatments, including those who did so for Health Canada (HC) approved treatments (50%) and those who discussed off-label treatments (i.e., not HC approved) as guided by national guidelines (48%). Respondents in practice for over 15 years versus less than 5 years (OR 0.14, 95% CI 0.04–0.50, p = 0.002) and those who worked in a community practice versus comprehensive cancer center (OR 0.17, 95% CI 0.03–0.91, p = 0.04) were significantly less likely to discuss off-label treatment options with their patients. Almost half of respondents (47%) indicated that their institution did not permit the administration of unfunded treatments. Conclusions: There is variability in medical oncologists’ practices when it comes to discussing unfunded therapies. Given the limitations within Canada’s publicly funded healthcare system, physicians are faced with the challenge of navigating an increasingly complex balance between patient care and available resources. Engagement of relevant stakeholders and policy makers is crucial in the continued evaluation of Canada’s drug funding process.

[1]  M. Trudeau,et al.  Pan-Canadian Oncology Drug Review (pCODR): A unique model to support harmonization of cancer drug funding decisions in Canada. , 2018, Journal of Clinical Oncology.

[2]  Kelvin K. W. Chan,et al.  The economic burden of cancer care in Canada: a population-based cost study. , 2018, CMAJ open.

[3]  M. Stockler,et al.  Discussing and prescribing expensive unfunded anticancer drugs in Australia , 2017, ESMO Open.

[4]  J. Peppercorn,et al.  Physician Experience and Attitudes Toward Addressing the Cost of Cancer Care. , 2016, Journal of oncology practice.

[5]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[6]  M. Mamdani,et al.  Overcoming obstacles in accessing unfunded oral chemotherapy: physician experience and challenges. , 2013, Journal of oncology practice.

[7]  J. Mellor,et al.  Access to anticancer drugs: many evidence‐based treatments are off‐label and unfunded by the Pharmaceutical Benefits Scheme , 2012, Internal medicine journal.

[8]  Kelvin K. W. Chan,et al.  Less than ideal: how oncologists practice with limited drug access. , 2012, Journal of oncology practice.

[9]  C. Bell,et al.  Variation and consternation: access to unfunded cancer drugs in Canada. , 2012, Journal of oncology practice.

[10]  L. Fallowfield,et al.  The views of patients and the general public about expensive anti-cancer drugs in the NHS: a questionnaire-based study , 2011, JRSM short reports.

[11]  A. Culyer,et al.  Access to cancer drugs in Canada: looking beyond coverage decisions. , 2011, Healthcare policy = Politiques de sante.

[12]  J. Savulescu,et al.  To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Douglas K. Martin,et al.  The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study , 2007, BMC Health Services Research.

[14]  D. Schrag,et al.  Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Savulescu,et al.  Do oncologists discuss expensive anti-cancer drugs with their patients? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.